User login
Key clinical point: Adebrelimab plus chemotherapy improves overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC).
Major finding: The adebrelimab vs. placebo group demonstrated a longer median OS (15.3 vs. 12.8 months; hazard ratio 0.72; one-sided P = .0017). The frequency of treatment-related serious adverse events was 39% in the adebrelimab group vs. 28% in the placebo group.
Study details: This randomized, double-blind, placebo-controlled phase 3 CAPSTONE-1 trial included patients with ES-SCLC who were randomly assigned to receive the first-line adebrelimab (n = 230) or placebo (n = 232) on day 1 of each cycle plus chemotherapy (carboplatin and etoposide).
Disclosures: The study was funded by Jiangsu Hengrui Pharmaceuticals. C Zhou reported ties with multiple pharmaceutical companies. B Zhang, W Shi, and X Zhang are employees of Hengrui Pharmaceuticals. The other authors declared no competing interests.
Source: Wang J et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739-747 (May 13). Doi: 10.1016/S1470-2045(22)00224-8
Key clinical point: Adebrelimab plus chemotherapy improves overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC).
Major finding: The adebrelimab vs. placebo group demonstrated a longer median OS (15.3 vs. 12.8 months; hazard ratio 0.72; one-sided P = .0017). The frequency of treatment-related serious adverse events was 39% in the adebrelimab group vs. 28% in the placebo group.
Study details: This randomized, double-blind, placebo-controlled phase 3 CAPSTONE-1 trial included patients with ES-SCLC who were randomly assigned to receive the first-line adebrelimab (n = 230) or placebo (n = 232) on day 1 of each cycle plus chemotherapy (carboplatin and etoposide).
Disclosures: The study was funded by Jiangsu Hengrui Pharmaceuticals. C Zhou reported ties with multiple pharmaceutical companies. B Zhang, W Shi, and X Zhang are employees of Hengrui Pharmaceuticals. The other authors declared no competing interests.
Source: Wang J et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739-747 (May 13). Doi: 10.1016/S1470-2045(22)00224-8
Key clinical point: Adebrelimab plus chemotherapy improves overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC).
Major finding: The adebrelimab vs. placebo group demonstrated a longer median OS (15.3 vs. 12.8 months; hazard ratio 0.72; one-sided P = .0017). The frequency of treatment-related serious adverse events was 39% in the adebrelimab group vs. 28% in the placebo group.
Study details: This randomized, double-blind, placebo-controlled phase 3 CAPSTONE-1 trial included patients with ES-SCLC who were randomly assigned to receive the first-line adebrelimab (n = 230) or placebo (n = 232) on day 1 of each cycle plus chemotherapy (carboplatin and etoposide).
Disclosures: The study was funded by Jiangsu Hengrui Pharmaceuticals. C Zhou reported ties with multiple pharmaceutical companies. B Zhang, W Shi, and X Zhang are employees of Hengrui Pharmaceuticals. The other authors declared no competing interests.
Source: Wang J et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739-747 (May 13). Doi: 10.1016/S1470-2045(22)00224-8